Regeneron Announces Winners of the 2014 Regeneron Prize for Creative Innovation - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Regeneron Announces Winners of the 2014 Regeneron Prize for Creative Innovation 10 Promising Early-Career Biomedical Researchers Recognized


Regeneron Announces Winners of the 2014 Regeneron Prize for Creative Innovation

10 Promising Early-Career Biomedical Researchers Recognized

PR Newswire

TARRYTOWN, N.Y., June 2, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the second annual winners of the Regeneron Prize for Creative Innovation, an award designed to acknowledge, reward, and foster talented early-career biomedical scientists.  This year, Regeneron awarded $160,000 in prize money to 10 awardees and two institutions.

"The Regeneron Prize for Creative Innovation identifies and recognizes young scientists who show great promise to become the next generation of leading innovators in our industry," said George Yancopoulos, M.D., Ph.D., Founding Scientist, President, Regeneron Laboratories, and Chief Scientific Officer.  "Innovation in science and technology is at the heart of Regeneron's mission to discover and develop new treatments for serious diseases.  Investing in science education and the identification and development of talented new researchers is critical to foster tomorrow's medical breakthroughs."

Two winners of the Regeneron Prize will each receive a $50,000 cash prize.  The institutions nominating the two winners will also receive a donation to support their seminar series.  This year's winners are:

  • Daniel Schramek, The Rockefeller University, Regeneron Prize for Creative Innovation by a Postdoctoral Fellow
  • Kelly Clancy, Biophysics, University of California, Berkeley, Regeneron Prize for Creative Innovation by a Graduate Student

Two graduate student researchers will be awarded Honorable Mentions and a cash prize of $10,000 each:

  • Daniel Marks, Cancer Biology, Gerstner Sloan Kettering Graduate School
  • Xuebing Wu, Computational and Systems Biology, Massachusetts Institute of Technology

Six additional finalists will each be awarded $5,000.

Requests for applicants were distributed to academic institutions in January 2014.  Each institution was asked to nominate two graduate students and two postdoctoral fellows.  Each nomination includes a proposal explaining the nominee's "dream" project in biomedical research, which offers insight into the nominee's creativity and ability to think independently as a scientist.  Each nomination also includes a curriculum vitae, list of publications and a review of the nominee's productivity in their current laboratory.

"We look for young scientists who demonstrate the capacity for original thinking and for research proposals that have the potential to drive biomedicine forward," said Susan Croll, Ph.D., Regeneron scientist and director of the postdoctoral program at Regeneron.  "This year's winners more than met this standard."

About Regeneron Pharmaceuticals
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis.  For additional information about the company, please visit www.regeneron.com.                                                                                   


Contact Information:





Manisha Narasimhan, Ph.D.            



Hala Mirza

Investor Relations



Corporate Communications

914.847.5126



914.847.3422

manisha.narasimhan@regeneron.com



hala.mirza@regeneron.com





SOURCE Regeneron Pharmaceuticals, Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here